Keywords: ApoPharma, Apotex, Ferriprox, Iron overlead, USA, FDA
FDA approves ApoPharma’s Ferriprox to treat patients with iron overload
Article | 17 October 2011
The US Food and Drug Administration on Friday approved Ferriprox (deferiprone), from ApoPharma, a subsidiary of Canadian generics major Apotex, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
